SparX Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 50

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $36M

  • Investors
  • 3

SparX General Information

Description

Developer of nanobody-based biopharmaceutical therapeutics designed for immuno-oncology research and development serving the pharmaceutical industry. The company offers antibody drug conjugate and bispecific antibody platforms, including dual-payload and biparatopic nanobody architectures with artificial intelligence-enabled discovery and in-house current good manufacturing practice production, enabling drug developers to generate and advance oncology candidates with integrated translational and clinical development capabilities.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 700 East Business Center Drive
  • Mount Prospect, IL 60056
  • United States
+1 (847)
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Corporate Office
  • 700 East Business Center Drive
  • Mount Prospect, IL 60056
  • United States
+1 (847)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SparX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series B) 31-Dec-2021 $36M Completed Clinical Trials - Phase 1
To view SparX’s complete valuation and funding history, request access »

SparX Patents

SparX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2021257822-A2 Bispecific antibodies targeting human claudin 18.2 and programmed death-ligand 1 (pd-l1) Inactive 18-Jun-2020
WO-2021257822-A3 Bispecific antibodies targeting human claudin 18.2 and programmed death-ligand 1 (pd-l1) Inactive 18-Jun-2020
US-20210188897-A1 Neuroactive steroids and compositions and methods thereof Inactive 05-Dec-2019
WO-2021113068-A1 Neuroactive steroids and compositions and methods thereof Inactive 05-Dec-2019
JP-2024159749-A Binding molecules specific for claudin 18.2, compositions and methods thereof, for treatment of cancer and other diseases Inactive 28-Dec-2018 C07K16/28
To view SparX’s complete patent history, request access »

SparX Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SparX Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Highlight Capital Venture Capital Minority
Shenzhen Qianhai Rotating Stone Fund Management Growth/Expansion Minority
Shenzhen Sangel Venture Capital Venture Capital Minority
To view SparX’s complete investors history, request access »

SparX FAQs

  • When was SparX founded?

    SparX was founded in 2018.

  • Where is SparX headquartered?

    SparX is headquartered in Mount Prospect, IL.

  • What is the size of SparX?

    SparX has 50 total employees.

  • What industry is SparX in?

    SparX’s primary industry is Drug Discovery.

  • Is SparX a private or public company?

    SparX is a Private company.

  • What is SparX’s current revenue?

    The current revenue for SparX is .

  • How much funding has SparX raised over time?

    SparX has raised $36M.

  • Who are SparX’s investors?

    Highlight Capital, Shenzhen Qianhai Rotating Stone Fund Management, and Shenzhen Sangel Venture Capital have invested in SparX.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process